8-K: Voyager Therapeutics Reports Promising Tau Silencing Gene Therapy Data and Extends Cash Runway into Mid-2027

Voyager Therapeutics announces positive results from its tau silencing gene therapy program and extends its cash runway into mid-2027, driven by advancements in its Alzheimer's disease and partnered programs.

Summary

• Voyager Therapeutics reported its fourth quarter and full year 2024 financial and operating results.
• The company's tau silencing gene therapy, VY1706, showed robust reductions in tau mRNA levels in a non-human primate study and is expected to enter IND-enabling studies.
• The anti-tau antibody, VY7523, was well-tolerated in healthy volunteers and is currently in a multiple ascending dose study in Alzheimer's patients, with initial tau PET imaging data expected in the second half of 2026.
• Voyager's cash runway has been extended into mid-2027 due to the company no longer advancing VY9323, its previous lead development candidate for SOD1 ALS.
• Collaboration revenue for the fourth quarter of 2024 was $6.3 million, compared to $90.1 million for the same period in 2023.
• Net loss for the fourth quarter of 2024 was $34.5 million, compared to net income of $56.4 million for the same period in 2023.
• Cash, cash equivalents, and marketable securities as of December 31, 2024, were $332.4 million.
• The company anticipates multiple IND filings in 2025 with Neurocrine-partnered gene therapies and for Friedreichs ataxia.

Sentiment

Score: 7

Explanation: The document presents a mixed sentiment. While there are positive developments in the pipeline and an extended cash runway, the decrease in collaboration revenue and net loss raise concerns. The overall sentiment is cautiously optimistic.

Positives

• The tau silencing gene therapy VY1706 showed promising results in reducing tau mRNA levels.
• The anti-tau antibody VY7523 was well-tolerated in clinical trials.
• Voyager has a strong cash position of $332.4 million as of December 31, 2024.
• The company has extended its cash runway into mid-2027.
• Voyager anticipates multiple IND filings in 2025.

Negatives

• Collaboration revenue decreased to $6.3 million for the fourth quarter of 2024, compared to $90.1 million for the same period in 2023.
• Net loss was $34.5 million for the fourth quarter of 2024, compared to net income of $56.4 million for the same period in 2023.
• Voyager is no longer advancing VY9323, its previous lead development candidate for SOD1 ALS.

Risks

• The success of Voyager's product candidates is subject to regulatory approvals and clinical trial outcomes.
• The willingness and ability of Voyager's collaboration partners to meet obligations under collaboration agreements could impact revenue.
• The development by third parties of competitive capsid identification platforms could impact Voyager's TRACER platform.
• Voyager's ability to protect intellectual property rights associated with its TRACER capsid discovery platform is crucial.
• Voyager's cash resources may not be sufficient to fund its operations and pursue its corporate objectives.

Future Outlook

Voyager expects its cash, cash equivalents, and marketable securities, along with amounts expected to be received as reimbursement for development costs under the Neurocrine and Novartis collaborations and interest income, to be sufficient to meet Voyager's planned operating expenses and capital expenditure requirements into mid-2027.

Management Comments

• Our anti-tau antibody VY7523 is now in a clinical trial in Alzheimers disease patients, and our tau silencing gene therapy VY1706 is now in IND-enabling studies, said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager.
• At the same time, we made significant progress across our partnered portfolio of IV gene therapy programs in 2024, generating approximately $80 million in non-dilutive funding last year alone.
• Our strong cash position is expected to provide runway through multiple value-creating milestones and into mid-2027, and this does not include potential milestone payments from existing partnerships.

Industry Context

Voyager's focus on tau as a target in Alzheimer's disease aligns with growing interest in this area, as evidenced by third-party data demonstrating the impact of anti-tau antibodies on tau accumulation in the human brain. The company's advancements in gene therapy and antibody programs position it competitively in the neurological disease treatment landscape.

Comparison to Industry Standards

• Voyager's approach to Alzheimer's disease, focusing on tau, is comparable to companies like Biogen and Eli Lilly, which are also developing anti-tau therapies.
• The 50-73% reduction in tau mRNA levels with VY1706 in NHPs is a promising result, potentially competitive with other gene silencing approaches in development.
• The CSF-to-serum ratio of 0.3% for VY7523 suggests good penetration into the central nervous system, a key factor for antibody therapies targeting neurological diseases.
• Voyager's cash runway into mid-2027 provides a stable financial outlook, comparable to other biotech companies with similar pipelines and partnered programs.

Stakeholder Impact

• Shareholders may be encouraged by the positive clinical data and extended cash runway.
• Employees may benefit from the company's continued investment in research and development.
• Patients with neurological diseases may have access to new treatment options through Voyager's pipeline programs.
• Collaboration partners may see increased value in their partnerships with Voyager.

Next Steps

• Voyager expects to present additional data from the NHP study of VY1706 at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (ADPD) April 1-5, 2025.
• The company anticipates multiple IND filings in 2025 with Neurocrine-partnered gene therapies and for Friedreichs ataxia.
• Initial tau PET imaging data is expected in the second half of 2026 in the MAD clinical trial of VY7523 in AD.

Key Dates